Safety of maternal drug therapy during breastfeeding may be assessed from estimated levels of drug exposure of the infant through milk.Pharmacokinetic (PK) principles predict that the lower the clearance is, the higher the infant dose via milk will be. Drugs with low clearance (<1 mL/[kg·min]) are likely to cause an infant exposure level greater than 10% of the weight-adjusted maternal dose even if the milk-to-plasma concentration ratio is 1. Most drugs cause relatively low-level exposure below 10% of the weight-adjusted maternal dose, but opioids require caution because of their potential for severe adverse effects. Furthermore, substantial individual variations of drug clearance exist in both mother and infant, potentially causing drug accumulation over time in some infants even if an estimated dose of the drug through milk is small. Such PK differences among individuals are known not only for codeine and tramadol through pharmacogenetic variants of CYP2D6 but also for non-CYP2D6 substrate opioids including oxycodone, indicating difficulties of eliminating PK uncertainty by simply replacing an opioid with another. Overall, opioid use for pain management during labor and delivery and subsequent short-term use for 2-3 days are compatible with breastfeeding. In contrast, newly initiated and prolonged maternal opioid therapy must follow a close monitoring program of the opioid-naive infants. Until more safety data become available, treatment duration of newly initiated opioids in the postpartum period should be limited to 2-3 days in unsupervised outpatient settings. Opioid addiction treatment with methadone and buprenorphine during pregnancy may continue into breastfeeding, but infant conditions must be monitored.
Although 80% to 90% of postpartum women in many countries initiate breastfeeding, 1 as many as 80% of them need medications during breastfeeding. 2, 3 However, risk assessment to avoid potential drug toxicity in the infant is difficult because lactating women are excluded from drug development processes, causing lack of information on drug levels in milk when the drug is introduced into the market. Even in postmarket settings, data on pharmacokinetics (PK) in milk are limited, creating an information vacuum of first-line evidence necessary for the risk assessment. A default decision to stop breastfeeding is not an option because of the tremendous health benefits of breast milk to the infant, which include enhanced cognitive development, lower risks of infection, and immune system development. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] In fact, professional organizations such as the American Academy of Pediatrics recommend exclusive breastfeeding at least for the first 6 months of life, 4 although such a view of pediatricians may not be widely known outside the discipline. In fact, even if there is well-balanced safety information during breastfeeding for a particular drug, patients are often advised against breastfeeding, or they avoid taking necessary drugs, due to lack of rational risk assessment. Studies indicate that almost half of women on medications with safety information discontinue breastfeeding. [15] [16] [17] When drug therapy continues, cases of infant drug toxicity emerge, 18 including a tragic case of fatality due to maternal codeine use. 19 It is important for all health professionals to recognize the unique aspect of drug safety assessment during breastfeeding. In particular, basic understanding of PK principles of infant drug exposure through milk and its application to clinical cases constitute a skill set essential for a clinical pharmacologist. In this article the focus is placed on opioids because of their serious adverse effect profiles.
Benefits of Breastfeeding
In the risk assessment of drug safety during lactation, benefits of breast milk for the health of both mother and infant must be made explicit. 4 Although evidence for benefits of breast milk has been obtained mostly from observational cohort studies and epidemiological analyses, presence of biological plausibility as well as close and frequently observed associations between breastfeeding and various health benefits suggests causal relationship. First, breast-fed infants are less prone to infection, [6] [7] [8] [9] which may be at least partly as a result of anti-infective substances in breast milk such as secretory IgA, lactoferrin, lysozymes, and defensins. Importantly, the incidence of necrotizing enterocolitis in preterm infants is significantly reduced when breast milk is used. 4, 10 Second, breastfed infants show better cognitive development than formula-fed counterparts. 13, 14 Coupled with findings from observational cohort studies, results of a randomized trial of intense breastfeeding promotion (PROBIT trial) indicate that breastfeeding is associated with higher IQ at 6-7 years of age. 13 Overall, the IQ increase in this study was about 8 points, which are half of the standard deviation of IQ in the general population, implying a midsize impact on the population. Third, mouse experiments suggest that maternal cytokines in milk, together with allergens the mother ingested, affect infant immunological recognition of exogenous antigens by developing tolerance to them. 20 Such a function may be viewed as a role of the lactating mammary gland as an information-processing organ for the infant who needs to be prepared to deal with the surrounding habitat after weaning. It is fair to assume that there remain other important biological functions of breast milk, which have yet to be discovered. Given these beneficial effects of breast milk, the current practice guideline for pediatricians recommends exclusive breastfeeding for the first 6 months of life and further continuation of breastfeeding thereafter. 4 In the risk assessment of maternal drug in breastfeeding, any decision to discontinue breastfeeding must be carefully balanced with the lack of these health benefits that breast milk may otherwise provide.
Mechanism of Drug Transfer Into Milk
The mammary gland epithelia constitute the ducts and the secreting alveoli. Milk is secreted into the alveoli, which are surrounded by myoepithelial cells with the ability to contract on stimulation by oxytocin. 21, 22 The alveoli are embedded in the interstitial tissues, which contain blood vessels. After progesterone-dependent proliferation of the ductal structures in pregnancy, the lactogenic hormone prolactin completes the lobuloalveolar growth for lactation. 23, 24 Drugs in the interstitial compartment get in contact with mammary gland epithelia. There are multiple mechanisms of drug secretion into milk, which include, but are not limited to, passive and facilitated diffusion and active transport. 25 Clinical observations of drug concentrations in milk and maternal plasma indicate that a combined model of diffusion and active transport, particularly breast cancer-resistant protein (BCRP)-mediated efflux into milk, may explain the milk disposition patterns of many drugs. 26, 27 BCRP is highly expressed in tissues with a barrier function, including vascular endothelial cells in the brain (ie, blood-brain barrier), placental syncitiotrophoblast, and intestinal epithelia, as an efflux transporter reducing exposures of brain, fetus, and host organs to drugs and toxins. 28 The substrate spectrum of BCRP is relatively wide, including phytochemicals, food toxins, and drugs (eg, cimetidine, acyclovir, nitrofurantoin, and methotrexate).
28 Surprisingly, the lactating mammary gland was shown to highly express BCRP 29 through the prolactin-JAK2/STAT5 pathway. 30 Later, a new role of BCRP in the mammary gland was discovered when milk of Bcrp-null mice was found to lack vitamin B 2 (riboflavin). 31 This finding defined the function of mammary gland BCRP as a vitamin B 2 transporter, consistent with the essential vitamin status of riboflavin and its accumulation in milk. Drugs and toxins that are BCRP substrates apparently hijack the transporter.
This model of combined diffusion and active transport suggests that both diffusion-related factors (eg, ionization characteristics, plasma protein binding, and lipophilicity) and substrate specificity for BCRP are key indicators for levels of drug secretion into milk. Specifically, BCRP substrates, cationic nature (because milk compartment is more acidic than maternal plasma, basic drugs tend to be more ionized in milk, unable to diffuse back to plasma), low plasma protein binding, and high lipophilicity are important elements of increased milk transfer relative to absence of these characteristics. These factors independently influence drug concentration in milk, collectively defining a milkto-plasma drug concentration ratio (MP ratio).
Parameters of Drug Transfer Into Breast Milk
The MP ratio is defined as a ratio of the area under the concentration-time curve (AUC, or average concentrations) between milk and maternal plasma. 25 Because of the difficulty in obtaining AUC data, the MP ratio is often estimated from a single data point as a surrogate, which may or may not reflect AUC-based MP ratio values because concentration-time profiles may be different between milk and maternal plasma. Although MP ratio is a concept easy to understand, it is sometimes overinterpreted as a sole determinant of the infant drug exposure level. 18 This leads to a misconception that drugs with an MP ratio of greater than 1 are unsafe because of the accumulation. This notion is not necessarily true and is actually untrue for most cases because infant exposure levels to the drug in milk are determined not only by the MP ratio but also by drug clearance.
Relative infant dose (RID) is a weight-adjusted timeaveraged (eg, daily) dose of drug in milk ingested by the infant, expressed as a percentage of the timeaveraged maternal therapeutic dose on a body weight basis. A RID of 100% is the same as directly receiving a therapeutic dose per weight; RID 10% means that infant dose of drug via milk is 10% of the therapeutic dose per body weight. A RID of 10% is often considered a reference point as a safety threshold in risk assessment, 25 but lower values such as 5% may be considered a threshold of breastfeeding acceptability for psychoactive drugs. 32 These cutoff values of RID are not a toxicity threshold but rather theoretical reference points for risk assessment. By definition, RID is a parameter of infant drug exposure relative to maternal therapeutic dose per kg, instead of neonatal therapeutic dose per kg. Although it is obviously best to use a neonatal therapeutic dose for comparison with infant drug exposure through milk, most drugs lack information on neonatal doses. Therefore, if there is evidence of lower clearance of the drug in the neonatal period, the RID may be adjusted accordingly at the final phase of the risk assessment. 18 
Pharmacokinetic Principles
The above concepts can be expressed as a simple PK principle. 18 Briefly, the daily amount of drug the infant would ingest via milk is: 
where τ is a dosing interval, F is bioavailability, and CL is total body clearance of the drug in the mother. Therefore, we can obtain:
×daily milk intake Assuming that F = 1, RID can be rewritten as a percentage parameter:
Milk intake of an infant is usually assumed to be 150 mL/(kg·day) (ß0.1 mL/[kg·min]). 25, 33 Therefore,
where EI is exposure index, and a unit of CL is mL/(kg·min). When this PK principle was derived, the term EI was used 18, 34 instead of RID to emphasize the theoretical nature of the concept. Indeed, EI may be calculated from the MP ratio predicted by physicochemical properties of the drug 26 and reported CL values. This PK principle (equation 1) can be visualized as a hyperbolic relationship between RID and clearance ( Figure 1 ). Because MP ratio and CL are independent parameters with their own ranges of observed values, drugs are distributed in a relatively limited area in this space. Furthermore, as seen in Figure 1 , influences of MP ratio on RID are pronounced for a relatively few drugs with low clearance, compared to those with high clearance, implying that clinical significance of MP ratio depends on clearance of the drug. Interestingly, reported MP ratios of most drugs are around 1 or lower, and most drugs have clearance of greater than 1 mL/(kg·min). 34 Therefore, most drugs are unlikely to achieve RID greater than 10%. However, drugs with relatively low clearance (eg, <<1 mL/[kg·min]) have greater potential to achieve higher RID. In other words, those drugs with relatively low CL may be warranted for drug monitoring in milk as far as dosedependent effects are concerned. In addition, if infant drug clearance is substantially lower than that of an adult per body weight, then this must be taken into account when interpreting RID as described next.
Impact of Infant Clearance on Drug Exposure Levels
The PK principles described above may be applied to some clinical examples as follows. Theoretically, it is defined by maternal drug clearance (CL) and milk-toplasma (MP) ratio of drug. RID of 100% means that the infant would be exposed to the drug in milk at a dose/time equivalent to the mother's dose/time per weight. MP ratios of most drugs are around 1 or less. CL is expressed as mL/[kg·min]. Bioavailability is assumed to be 1 in this graph.
Scenario 1
A mother starts atenolol 100 mg/day (1.5 mg/[kg·day]) at 2 weeks postpartum for hypertension. Reported RID of atenolol ranges from 5% to 19%. 35 If 10% RID is assumed for this mother, her infant would ingest merely one-tenth of the maternal therapeutic dose on a body weight basis: 0.15 mg/(kg·day). Assume that her breastfed infant has renal dysfunction, and creatinine clearance remains low at 0.5 mL/(kg·min) (30% of a maturity level). Because his glomerular filtration rate is at 30% of a mature adult level (ie, atenolol clearance/kg is also 30% of the mature level), he will achieve a therapeutic plasma concentration at steady state with only a third of the adult therapeutic dose per kilogram. Therefore, a "RID of 10%" must be interpreted with caution for this infant due to his significantly reduced drug clearance. If infant clearance is further reduced to 10% of the mature level, then the infant dose through milk becomes close to 100% of the therapeutic dose for the infant. In this circumstance, it will take about a week to reach a steady-state therapeutic plasma concentration due to a prolonged elimination half-life (10 × normal half-life of 6 hours = 60 hours).
Scenario 2
A woman who is a liver transplant recipient with oral tacrolimus monotherapy 0.05 mg/(kg·day) delivered a healthy term baby. If drug therapy of the mother starts during or before pregnancy, drug concentrations in infant blood at birth may be close to a maternal level. Indeed, tacrolimus concentration in cord blood is about 70% of the corresponding maternal level. The RID of tacrolimus is <0.3%, and these patients are encouraged to breastfeed. The activity of its metabolizing enzyme CYP3A is relatively well developed in neonates and infants at a level of about 40% to 50% of the mature level. In this case, infant blood levels of tacrolimus will decline continuously as CYP3A function further develops even if they are breastfed by those women. Differences in blood level decline and final steady state levels between breast-fed and formula-fed infants are likely to be too small to be detected. If infant drug clearance remains pathologically low for a prolonged period of time, or if RID is relatively high, postnatal decline of plasma drug levels may be blunted by drug exposure via breast milk. This scenario is important for the management of breastfeeding women on methadone treatment and will be discussed later.
Adverse Outcomes of Infant Drug Exposure via Milk
Although the majority of studies report uneventful uses of maternal medications during breastfeeding, there exist case reports of breast-fed infants with adverse events, which appear to have resulted from drug in breast milk. Given the relatively low RID for most drugs, pharmacologically meaningful exposures of healthy breast-fed infants are unlikely at least for short-term effects. However, some of these toxicity case reports seem to represent important outliers: significantly reduced drug clearance of the infant, causing accumulation of the drug over a period of time even if each dose via milk is small. The other potential mechanism is altered pharmacodynamics, such as reduced function of blood-brain barrier and/or changes in target protein function, although these 2 mechanisms are not mutually exclusive. One example of the former mechanism may be the fatal toxicity case from maternal use of codeine during breastfeeding (see below: Codeine). 19 For the latter, some case reports suggest immediate emergence or disappearance of infant symptoms relative to respective changes in drug exposure through breastfeeding (eg, emergence of adverse effects in the infant after a couple of feeding episodes by the mother on methadone 35 or cessation of breastfeeding during methadone therapy followed shortly by development of opioid withdrawal in the infant 36 ), which are difficult to explain only from the PK principles of drug in milk.
Because opioids are characterized by serious adverse effect profiles, clear understanding of their use during breastfeeding is extremely important. The next sections focus on commonly used opioids in the context of breastfeeding.
Opioid Use in Breastfeeding
For the purpose of acute pain management, aroundthe-clock use of opioids by the mother during breastfeeding should be limited to less than 2-3 days 37 in unsupervised outpatient settings unless close monitoring of the infant condition is possible because adverse effect profiles of opioids are potentially life threatening (such as respiratory depression). Opioid RID is usually low on average in the range of 1% to 5% of the mother's therapeutic dose on a weight basis, although individual variations exist. Avoiding long-term use (more than 3-4 days) is to circumvent potential drug accumulation in the infant in case of significantly reduced drug clearance, which cannot be usually predicted a priori. Limiting the use to a few days is reasonable for the purpose of acute pain control. This view is apparently more cautious than the recommendation in favor of breastfeeding during methadone maintenance therapy discussed later, which is a long-term use almost throughout the duration of breastfeeding. This is partly because safety data are relatively scarce on long-term opioid use (eg, 1-2 weeks) for analgesic purposes during breastfeeding, compared to methadone therapy for opioid dependence. In addition, the infant populations in these 2 circumstances are different with regard to gestational opioid exposure and therefore infant sensitivity to opioids. Whether to continue breastfeeding with opioids if long-term pain management is needed in pregnancy and breastfeeding is a difficult clinical decision nonetheless.
The following sections describe some of the commonly used opioids for their use during breastfeeding in the context of maternal pain management and opioid dependence treatment (Table 1) , because clinical contexts are different between the 2 maternal conditions. The key findings of the representative reports of each opioid [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] are also described in Table 1 , which is not a comprehensive list of all relevant studies but rather a summary as a quick reference.
Pain Management
Morphine. Metabolism of morphine, as well as hydromorphone and oxymorphone, is through UGT2B7-mediated glucuronidation. 50 Importantly, one of the morphine glucuronides, morphine 6-glucuronide (M6G), is a potent μ-opioid receptor agonist, 51 which achieves severalfold higher AUC than morphine in adults after oral administration, although the ratio is highly variable among individuals (M6G/morphine molar AUC ratio ranges from about 2 to more than 9). 52 Brain penetration of M6G may be in the same range as that of morphine itself, implying a major contribution of M6G to pharmacological effects of morphine. 52 In term neonates (age 3 to 15 days) who received morphine continuous infusion for surgery, the mean plasma concentration ratio of M6G/morphine at steady state was 3.4 in a weight unit, 53 which is about 2 in a molar unit, suggesting that neonates may produce M6G to account for pharmacological effects, but the conversion is less than the adult level. 52 In premature neonates during the first 2 days of life, M6G/morphine ratio in plasma was reported to be 0.8 in a weight unit, 54 which is about 0.5 in a molar unit. UGT2B7-mediated M6G production pathway is not fully developed in neonates and infants, but its clinical implication is not understood well.
Morphine and M6G are excreted into milk. During a 48-hour morphine infusion (an average cumulative dose of 60 mg), both morphine and M6G were detected in milk (colostrum). 38 This study of 7 women immediately after cesarean section showed that median values of morphine and M6G concentrations in milk at 5 time points over the 48-hour period were 6.5-34 ng/mL and 273-672 ng/mL, respectively (note that this is based on 3 individuals who had detectable levels). 38 Using these median values and colostrum intake of 100 mL/day, we may estimate that an exclusively breast-fed infant would ingest about 2.4 μg/(kg·day) of morphine and 73 μg/(kg·day) of M6G (46 μg/[kg·day] as morphine equivalent). The total exposure to morphine and M6G becomes approximately 48 μg/(kg·day) of morphine equivalent, nearing a maintenance dose range of intravenous morphine for analgesia in a neonate. This may be an overestimate because oral bioavailability of morphine and M6G in an adult is 30% and 10%, respectively, 55 but data in the neonatal period are lacking. In addition, it is important to note that these findings are based on the first 2 days postpartum, which are likely to be characterized by high morphine-to-M6G clearance due to pregnancy-associated induction of UGT2B7. 56 Overall, RID of morphine alone without taking into account M6G is about 2% to 3% of the weightadjusted maternal morphine dose (Table 1 ). However, as described above, M6G exposure could be at a relatively high level, and its bioavailability in neonates is not known. Short-term morphine administration to the mother around delivery or post-cesarean section is compatible with breastfeeding. Although increased incidence of infant adverse events during maternal morphine treatment is not reported, close infant monitoring is indispensable, and postpartum use should not exceed 2-3 days in outpatient settings unless the infant's condition is closely monitored.
Codeine. CYP2D6 converts about 5% to 10% of codeine to morphine in the majority of individuals.
Because of its distinct gene polymorphism, CYP2D6 activity ranges widely from very low in poor metabolizers (eg, about 10% of people of European descent and smaller percentage in other populations) to extremely high in ultrarapid metabolizers (eg, due to copy number variants such as duplication seen in as high as 30% of people in northern Africa). 57 The magnitude of morphine conversion depends on these variant types, influencing pharmacological efficacy and toxicity of codeine, 58 as codeine itself is not highly active. As described above, morphine is further metabolized by UGT2B7, and 1 of its metabolites, M6G, is highly active. 50, 52 Although UGT2B7 is also polymorphic, intergenotype variation of morphine 6-glucuronidation has not been observed. 59 Based on codeine and morphine concentrations in milk, Findley et al 41 reported that at a maternal codeine use of 60 mg every 4 hours (360 mg/day), average milk levels were estimated to be about 350 ng/mL codeine and 42 ng/mL morphine, and RID is 1.2% of the maternal codeine dose (Table 1 ). This relative milk profile of the parent opioid (codeine)/active metabolite (morphine) is similar, if not identical, to tramadol milk disposition as described later. Although it appears unlikely that RID exceeds 10% even if the mother is a CYP2D6 ultrarapid metabolizer, this study did not take into account M6G. As described in the section on morphine above, disposition of orally administered M6G in infants has not been reported.
An increased frequency of infant sedation has been observed when breastfeeding mothers take codeine, compared to a nonopioid control group. 60 Although uneventful use of maternal codeine in breastfeeding has also been reported, 61, 62 the fatal case 19 of a 13-day old infant breastfed by a mother on codeine-containing formulation, who happened to be a CYP2D6 ultrarapid metabolizer with a higher rate of codeine conversion to morphine, may be an important outlier. Based on the morphine level of the breast milk sample in this case (87 ng/mL), 19 it is estimated that the infant ingested only about 13% of the neonatal intravenous morphine maintenance dose per time (ie, 100 μg/[kg·day]), assuming 150 mL/(kg·day) of milk intake. Although highly speculative due to absence of data in this report on both premortem serum level of the infant and milk concentrations of codeine itself, significantly reduced infant clearance of morphine may have contributed to this tragic case, causing accumulation of morphine over 1-2 weeks, as described in scenario 1 (impact of infant clearance on drug exposure levels).
There are a couple of important lessons we can learn from this tragic case of codeine fatality. First, as described above for opioids in general, limiting postpartum codeine use to 2-3 days may have led to an uneventful outcome even in this case of maternal CYP2D6 ultrarapid metabolizer. Second, although the mother of this case was a CYP2D6 ultrarapid metabolizer, a simulation analysis suggested that long-term exposure causes accumulation in the infant with low clearance even if maternal CYP2D6 is a common wild type. 63 This highlights difficulty in the risk assessment based on maternal CYP2D6 variant types. The FDA now recommends avoidance of codeine (and tramadol) during breastfeeding 64 because maternal CYP2D6 variant status is not necessarily known in advance.
In the absence of the information on CYP2D6 genotype status, it is challenging to predict codeine/morphine disposition in milk. Even if maternal CYP2D6 status is a wild type, the mother may have relatively high CYP2D6 function in the early postpartum period due to pregnancy-associated CYP2D6 induction 56 and individual variations of the function. Although codeine may be used for 2-3 days, close monitoring of the infant is necessary.
Oxycodone. In order to circumvent morphine toxicity risks in the infant from maternal codeine use during breastfeeding, oxycodone has often been suggested as an alternative; it is mainly metabolized by CYP3A to noroxycodone, a weakly active metabolite. 65 In fact, oxycodone is also metabolized by CYP2D6, generating oxymorphone, an active metabolite, but it is viewed as a minor pathway. 50, 66 Although both CYP3A and CYP2D6 mediate production of active metabolites of oxycodone, their plasma concentrations are not high enough to cause clinical effects, compared to oxycodone itself. 65 Also, inhibition of CYP2D6 by quinidine 67 or paroxetine 68 did not affect pharmacodynamic profiles of oxycodone, implying that the parent drug, oxycodone, gives rise to most of its therapeutic/toxic effects. Indeed, brain penetration of oxycodone appears far greater than its active metabolites in part due to its higher lipophilicity. 65 The current prevailing view is that oxycodone itself is the key active component, and therefore, oxycodone seems free of uncertainties surrounding codeine in relation to CYP2D6 pharmacogenetic variations. However, it is important to recognize that oxycodone clearance through CYP3A also varies widely among individuals.
Oxycodone clearance per body weight increases as the infant grows, reaching an adult level in a few months; median clearance per body weight in neonates younger than 1 week of age is about two-thirds of those in older infants and children. 69 This average picture of age-dependent increase of clearance along the developmental trajectory is associated with substantial individual variations within each respective age group, ranging from 20% to 200% of the median values. 69 Thus, lack of influence from the CYP2D6-related factors does not necessarily eliminate uncertainties stemming from individual variations in CYP3A-mediated oxycodone clearance in the mother and infant.
Data on milk PK of oxycodone is scarce. Based on one study, 42 we may predict RID in the range of 0.1% to 3% (Table 1) . Given the paucity of systematically acquired observation on oxycodone RID, theoretical assessment of average infant exposure level may be useful. Assuming that median maternal clearance is around 13.5 mL/(kg·min) (range 6.4-33.0) 70 and MP ratio of 3.2 (range 1.1-8.2), 42 equation 1 described before gives RID (or EI) of 2.4% (range 0.33% to 12.8%). (Note that bioavailability is assumed to be 1.) Although the average estimate of 2.4% of EI or RID is relatively small, a wide variation is anticipated, implying that an extreme case may achieve an infant dose via milk at more than 10% of the maternal dose on a weight basis. Because infant oxycodone clearance also varies widely, it is possible that some infants may receive oxycodone in milk at a relatively high level. In addition, pharmacodynamics of an opioid may be different between infants and adults. A cohort study with retrospective analyses of infant symptoms demonstrated that 20% of mothers on oxycodone reported signs of central nervous system depression in their breast-fed infants, compared to 0.5% in the acetaminophen group. 60 Interestingly, about 17% of these women on codeine in this study also reported infant symptoms. Although data on drug concentrations in milk were not examined in this study, it is unlikely that all of these symptomatic infants achieved plasma drug levels similar to those seen in adult patients receiving therapeutic doses of oxycodone or codeine. Rather, these observations suggest that neonates and infants are sensitive to opioid effects, compared to older children and adults. Although the sensitivity to opioid is likely to differ between those with and without intrauterine exposure, this has not been systematically examined.
Oxycodone may not be considered a safer alternative to codeine during breastfeeding. The general precaution for opioid use during breastfeeding (ie, no more than 2-3 days in unsupervised outpatient settings) should be taken when oxycodone is given to a breastfeeding woman.
Tramadol. A main metabolic pathway of tramadol is mediated by CYP2D6, which converts tramadol to O-desmethyltramadol (M1), an active metabolite. 71 In addition, about 30% of the orally administered dose is excreted unchanged in urine. 72 Tramadol is a racemic mixture, showing enantiomer-specific differences in receptor binding, and the following discussion applies to the racemic mixture unless otherwise specified.
Multiple mechanisms play a role in analgesic effects of tramadol. Tramadol itself is a very weak μ-opioid receptor agonist compared to morphine, and its effects are relatively insensitive to an opioid receptor antagonist, naloxone. 71 Although a CYP2D6-mediated active metabolite M1 has much higher affinity to μ-opioid receptor than the parent tramadol, morphine shows an order of magnitude higher affinity than (+)-M1. (+)-M1 is the main μ-opioid agonist, (+)-tramadol is also a serotonin reuptake inhibitor, and (−)-tramadol is an inhibitor of norepinephrine reuptake. 73 These multiple mechanisms seem to contribute to the overall therapeutic effects of tramadol. Because M1 metabolite is the main μ-opioid receptor agonist, tramadol may not exert enough analgesia in CYP2D6 poor metabolizers. 74 Importantly, significant respiratory depression is relatively infrequent in those on tramadol, compared to morphine or oxycodone at equipotent doses, 75 although at least 2 cases of respiratory depression in CYP2D6 ultrarapid metabolizers have been published: 1 case in a 66-year-old man with kidney dysfunction, 76 and the other in a 5.5-year-old boy after tonsillectomy. 77 In a study of 75 breastfeeding women, 43 milk tramadol and M1 metabolite concentrations were measured after 4 or more doses of 100 mg tramadol oral administration every 6 hours. Investigators reported tramadol milk levels ranging from <100 ng/mL to greater than 2400 ng/mL (mean 748 ng/mL) depending on postdose time (0-14 hours). M1 metabolite in milk also ranged widely from about 50 ng/mL to near 700 ng/mL (mean 203 ng/mL). The difference between tramadol and M1 metabolite levels in milk reflects their respective plasma concentrations because milkto-plasma ratios of the 2 compounds are similar 43 (mean MP ratio: tramadol 2.2; M1 2.8). Mean RIDs of tramadol and M1 in this study were 2.2% and 0.6% (as tramadol molar equivalent), respectively, which leads to total RID (tramadol + M1) of about 3% (Table 1) . The observed M1 concentrations in milk of these women suggest that infant exposure to the μ-receptor agonist, M1 metabolite, is small at least in this cohort, which was not characterized for their CYP2D6 genotype status. However, it is important to note that morphine as a codeine metabolite shows a similar milk profile as described before (ie, milk levels are 350 ng/ml codeine and 42 ng/ml morphine at codeine doses of 360 mg/day). 41 Differences in potency of μ-receptor activation between M1 and morphine may lead to differences in risk of respiratory depression in breastfed infants. This is a clinically important question, but it has not been fully addressed.
Tramadol has unique and complex mechanisms for its pharmacological actions. Given relatively weak effects on respiratory drive, tramadol may be preferred during breastfeeding, but the FDA discourages the use of codeine and tramadol in breastfeeding women and stipulates these as contraindicated for children younger than 12 years of age. 64 Further research is required to confirm the anticipated safer profile of tramadol use during breastfeeding.
Fentanyl. CYP3A-mediated metabolism is the main elimination pathway for fentanyl. Fentanyl is excreted in colostrum at very low concentrations following epidural or intravenous administration during delivery. At a maternal therapeutic dose range (eg, epidural administration at 100 μg; intravenous use of 100 μg/h), an estimated maximum dose of fentanyl the exclusively breast-fed infant would ingest is extremely low, in the range of about 0.02-0.06 μg/(kg·day). 45, 78 At present, there is no report indicating that fentanyl exposure through breastfeeding after maternal use during delivery causes clinically significant adverse effects.
Fentanyl is also used as a transdermal patch for control of chronic pain. In a case report, a fentanyl concentration in milk was 6.4 μg/L during maternal use of a patch at 100 μg/h dose. 44 Assuming an average milk intake of 150 mL/(kg·day), the infant would ingest about 1 μg/kg of fentanyl over a 24-hour period, which is approximately 2% to 3% of the maternal daily transdermal dose on a body weight basis (Table 1) . A RID of 2% to 3% is within the range seen in other opioids, suggesting that fentanyl use on a regular basis such as transdermal patch is compatible with breastfeeding. However, as seen for oxycodone, fentanyl clearance varies more than 10-fold among neonates. 79 Although fentanyl clearance increases as the infant grows, interindividual differences may cause higher sensitivity to the drug in some infants at a low end of clearance spectrum.
Given the paucity of safety data on the regular use of fentanyl for a long term during breastfeeding, close monitoring of the infant condition is necessary, whereas a short-term use appears relatively safe.
Opioid Dependence Treatment
Methadone. Intrauterine exposure to an opioid for a relatively prolonged period of time may cause neonatal opioid withdrawal (abstinence) syndrome. One of the questions in these circumstances is if breastfeeding should be recommended while the mother is on a medication-assisted therapy with methadone or buprenorphine for opioid addiction. The current guidelines from various sources including the American Academy of Pediatrics recommend breastfeeding for those women as long as other contraindication factors are absent such as HIV infection in developed country settings. 80 This recommendation is irrespective of the dose, although the infant must be observed for any sign of sedative effects.
Although multiple CYP enzymes and glomerular filtration are involved, CYP2B6 and CYP3A are considered the enzymes for methadone elimination, and there are no major active metabolites. 81 Pharmacological effects of methadone are complex, as it is a μ-opioid receptor agonist as well as an antagonist for the Nmethyl D-aspartic acid (NMDA) receptor. 82 Individual variations in methadone clearance may be substantial, reaching nearly 100-fold in cancer patients. 83 The RID of methadone in breastfeeding is around 1% to 3% (Table 1) , which may go up to 5% to 6% in a few cases. 37 At a maternal dose of 90 mg/day (eg, 1.5 mg/[kg·day]) of methadone, a RID of 1% to 3% amounts to an infant dose of about 0.015-0.045 mg/(kg·day), which seems too small to cause respiratory depression. However, in order to put this into perspective, we may compare this exposure level to the methadone treatment dose for neonatal opioid withdrawal syndrome, although morphine or buprenorphine is the current treatment of choice for neonatal opioid withdrawal. An initial dose of methadone for treatment of neonatal withdrawal is 0.1-0.2 mg/(kg·day), and a maximum dose is 1 mg/(kg·day), 84 indicating that a breast-fed infant of a mother receiving 90 mg/day of methadone is exposed to the drug at a dose ranging from 15% to 45% of the low end of the typical starting dose of methadone for neonatal opioid withdrawal. Because RID is based on 150 ml/(kg·day) of infant milk intake, this clearly overestimates the actual infant dose during the first several days when milk intake is relatively low. However, in a subset of infants, methadone dose through milk may reach 45% of the low-end therapeutic dose for neonatal opioid withdrawal. It is known that breastfeeding during methadone-assisted treatment for maternal opioid addiction alleviates infant withdrawal symptoms. 85, 86 Although this is likely a result of methadone in breast milk, it has yet to be convincingly demonstrated. Clearly, research is needed to elucidate the PK of methadone and its individual variations among breastfeeding women on methadone maintenance therapy including those with a relatively high dose (eg, >100 mg/day).
As long as infant conditions are monitored and regular pediatric follow-up is provided, breastfeeding is encouraged during methadone maintenance therapy of the mother. Indeed, many reports with various maternal doses indicate uneventful breastfeeding, although treatment of infant opioid withdrawal using morphine or buprenorphine is usually in place. [85] [86] [87] [88] [89] [90] Intrauterine exposure to methadone may make these infants less sensitive to opioid in breast milk, but this also remains to be systematically examined.
Buprenorphine. Buprenorphine is another opioid used sublingually for the treatment of pregnant women with opioid dependence. Compared to methadone, buprenorphine-assisted therapy of opioid addiction of pregnant women may result in milder withdrawal in the neonates. 91 Buprenorphine is a partial agonist of the μ-opioid receptor and is extensively metabolized by CYP3A. 92 Buprenorphine is a high-extraction-ratio drug, and its oral (duodenal) bioavailability is only about 10% due to extensive presystemic elimination. 93 Administration of buprenorphine as a sublingual formulation is to minimize the presystemic elimination, although bioavailability of sublingual formulations is still around 30% to 50%. 92 Although a main metabolite, norbuprenorphine, shows weak pharmacological activity, its clinical significance is questionable, and none of the final glucuronidated metabolite is considered active. During maternal buprenorphine (sublingual)-assisted therapy for opioid addiction at a mean dose of 9.3 mg/day, milk levels were 3.7 ng/mL on average, resulting in an estimated infant dose of 0.55 μg/(kg·day) ( Table 1) . 49 Other reports also indicate a similar range of milk levels and infant doses. [94] [95] [96] The RID of buprenorphine based on the reported average milk levels is less than 1% to 2% of the maternal sublingual dose adjusted by the body weight. 49, 94 Compared to infant sublingual doses for opioid withdrawal (ie, 15-60 μg/[kg·day]), 84, 97 the infant exposure levels to buprenorphine in milk in those reports are also in the range of <1% to 4% of the low end of the therapeutic infant dose. There have been a number of reported cases of uneventful breastfeeding during buprenorphine-assisted therapy for the maternal opioid addiction. [98] [99] [100] [101] In the context of buprenorphine-assisted treatment for maternal opioid addiction, breastfeeding should be encouraged with regular monitoring of infant conditions unless there is a contraindication factor for breastfeeding such as HIV infection.
Population PK Approach and Physiologically Based PK Modeling for Drugs in Breast Milk
Breastfeeding women and their infants are excluded from drug development processes, which is one of the causes of the absence of PK data in milk. Similarly, in postmarket settings, such milk PK data are difficult to obtain, and information on individual variations of infant exposure is virtually nonexistent, making it impossible to assess the likelihood of reaching certain drug concentrations in milk and infant plasma. Regulatory agencies have become aware of the dire situation, urging efforts from the stakeholders. 102 In this regard, methodological characteristics of the population PK approach with opportunistic sampling schedules, which are advocated for the pediatric population to facilitate PK data generation, appear attractive also for milk PK studies. 43, 103 Although a population PK approach can transform a relatively small number of milk level observations into a large-population data set of predicted milk levels and variations, a final component of the risk assessment requires prediction of plasma drug level distribution in the infants without exposing these otherwise healthy infants to the drug. Physiologically based PK modeling and simulation approaches have been increasingly recognized as useful tools to predict PK in pediatric patients. 104 The combination of population milk PK coupled to infant physiologically based PK models 63 will be increasingly used to facilitate data generation necessary for valid risk assessment in clinical settings.
Conclusions
Pharmacokinetic principles suggest that infant exposure levels become relatively high if the drug has low clearance (<<1 ml/[kg·min]) in the mother with no organ dysfunction. This is further accentuated if infant drug clearance is compromised. This notion provides an average picture of drug excretion into milk, but individual variations also need to be taken into account when the toxicity risk is assessed. Cases of infant drug toxicity through breastfeeding during maternal drug therapy are rare but represent clinically significant outliers. Without attention being paid to individual variations in drug exposure levels and infant responses, it will be difficult to construct a meaningful measure to predict the likelihood of such adverse events and prevent them while maximizing benefits of breastfeeding and maternal therapeutic gains. Because of their serious toxicity profiles, opioids constitute an important group of drugs. Average pictures of opioid exposure through breastfeeding suggest compatibility with breastfeeding. Specifically, average RID is not so high, in the range of 1-5% of the maternal weight-adjusted doses. However, variations in PK in the mother and infant may pose unacceptable risks to a subset of infants. Also, presence or absence of intrauterine exposures to opioids appears to be an important factor for infant sensitivity to opioids in breast milk. Opioid use by the mother during breastfeeding should be limited to 2-3 days for acute pain management in unsupervised outpatient settings. Breastfeeding is encouraged during maternal treatment of opioid dependence using methadone, particularly when the treatment started before or during pregnancy, but the mother-infant pairs should be monitored regularly. Research efforts should be made to elucidate PK variations in a population of breastfeeding motherinfant pairs.
